AI assistant
Pharnext — Regulatory Filings 2018
Jan 18, 2018
1594_iss_2018-01-18_9f31a561-f653-4cee-95cc-23684422136e.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Press Release
Pharnext's Pivotal Phase 3 trial PLEO-CMT to be featured at the 22nd Edition of the Francophone Peripheral Nerve Society conference
PARIS, France, 5:45 pm, January 18, 2018 (CET) – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).
| Date | Time | Session |
|---|---|---|
| Friday | From 3:03 | Selected Oral Communications Session |
| January 26, 2018 |
to 3:15pm CET |
• Title: Status of the Pivotal Phase III Study (PLEO-CMT) Assessing the Efficacy and Safety of PXT3003 in the Treatment of Adult Patients with Charcot-Marie-Tooth type 1A • Speaker : Prof. Shahram Attarian (Marseille) |
Details of the presentation are as follows:
For more information about the event please visit : www.journeessfnp.fr/programme
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287). For more information, visit www.pharnext.com.
CONTACTS:
Pharnext René Goedkoop Chief Medical Officer [email protected] +33 (0)1 41 09 22 30
Investor Relations (Europe) MC Services AG Anne Hennecke [email protected] +49 211 529252 22
Media Relations (Europe) ALIZE RP Caroline Carmagnol Aurore Gangloff [email protected] +33 (0)1 44 54 36 64
Investor Relations (U.S.) Stern Investor Relations, Inc. Matthew Shinseki [email protected] +1 212 362 1200
Media Relations (U.S.) RooneyPartners Marion Janic [email protected] +1 212 223 4017
Financial Communication (France) Actifin Stéphane Ruiz [email protected] +33 (0)1 56 88 11 15